

bsm-49050M**[Primary Antibody]****BioSS**
ANTIBODIES

www.bioss.com.cn

sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

CDV Fusion glycoprotein F0 Mouse mAb**— DATASHEET —****Host:** Mouse**Isotype:** IgG**Clonality:** Monoclonal**CloneNo.:** 4F2**Target:** CDV Fusion glycoprotein F0**Immunogen:** Recombinant Canine distemper virus Fusion glycoprotein F0: Fragment C-terminal.**Purification:** affinity purified by Protein A**Concentration:** 1mg/ml**Storage:** Size : 50ul/100ul/200ul


0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Size : 200ug (PBS only)

0.01M PBS

Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: Class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and plasma cell membrane fusion, the heptad repeat (HR) regions assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and plasma cell membranes. Directs fusion of viral and cellular membranes leading to delivery of the nucleocapsid into the cytoplasm. This fusion is pH independent and occurs directly at the outer cell membrane. The trimer of F1-F2 (F protein) probably interacts with H at the virion surface. Upon HN binding to its cellular receptor, the hydrophobic fusion peptide is unmasked and interacts with the cellular membrane, inducing the fusion between cell and virion membranes. Later in infection, F proteins expressed at the plasma membrane of infected cells could mediate fusion with adjacent cells to form syncytia, a cytopathic effect that could lead to tissue necrosis

Applications: WB (1:500-2000)**ELISA** (1:5000-10000)**Reactivity:** CDV**Predicted MW.:** 73 kDa**— VALIDATION IMAGES —**

20 ng Recombinant CDV Fusion Glycoprotein F0 protein, His (bs-49050P) per lane probed with CDV Fusion glycoprotein F0 monoclonal antibody respectively, unconjugated (bsm-49050M) at 1:1000 dilution and 4°C overnight incubation. Followed by corresponding conjugated secondary antibody incubation at r.t. for 60 min.